Medical Treatment for Urological Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 87
Special Issue Editor
2. Comprehensive Cancer Center, University Hospital of Munich, 81377 Munich, Germany
Interests: uro-oncology; precision medicine; circulating tumor DNA; targeted treatment
Special Issue Information
Dear Colleagues,
The past decade has been characterized by the advent of new therapeutic modalities for the medical treatment of prostate, urothelial and renal cancers. Classic and novel androgen deprivation therapy, cytotoxic chemotherapy, immune checkpoint inhibitors, tyrosine kinase inhibitors and antibody–drug conjugates are now the standard of care for the most common urologic malignancies. Moreover, the treatment paradigm is undergoing a dramatic shift with the advent of the first targeted therapies in uro-oncology, notably PARP and FGFR inhibitors, marking a pivotal moment in the management of these diseases.
This rapidly evolving landscape necessitates the reevaluation of treatment sequencing priorities, and will inevitably result in the phasing out of once-familiar substances from clinical guidelines. The objective of this Special Issue is to navigate the reader through these significant changes, offering insights into the future direction of medical treatment for urological cancers and highlighting the importance of adapting to these new therapeutic opportunities.
We look forward to receiving your contributions.
Dr. Jozefina Casuscelli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- urothelial cancer
- renal cancer
- antibody–drug conjugates
- cytotoxic chemotherapy
- immune checkpoint inhibitors
